Approval from USFDA - Zydus Lifesciences Ltd

Code BSE: 532321 NSE:

Zydus receives tentative approval from USFDA for Olaparib Tablets, 100 mg and 150 mg Olaparib is indicated for treatment of certain types of ovarian, breast, pancreatic, and prostate cancers in patients who have specific genetic mutations (specifically in the BRCA gene or other homologous recombination repair [HRR] genes). Olaparib tablets will be produced at Zydus Lifesciences Ltd, SEZ. Olaparib tablets had annual sales of USD 1,379.4 mn in the United States (IQVIA MAT Sept-2025)